NCT06649110View on ClinicalTrials.gov

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

232

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

November 29, 2028

Study Completion Date

December 31, 2028

Conditions
Healthy Volunteers, Pulmonary Arterial Hypertension
Interventions
DRUG

LTP

LTP001

DRUG

Placebo

Placebo

Trial Locations (1)

78744

RECRUITING

PPD Development LP, Austin

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY